Peri-Strips Dry with Veritas Collagen Matrix with Secure Grip Technology (PSDV-SG)
Device Facts
| Record ID | K192615 |
|---|---|
| Device Name | Peri-Strips Dry with Veritas Collagen Matrix with Secure Grip Technology (PSDV-SG) |
| Applicant | Synovis Life Technologies, Inc. (Baxter International Inc.) |
| Product Code | FTM · General, Plastic Surgery |
| Decision Date | Dec 17, 2019 |
| Decision | SESE |
| Submission Type | Traditional |
| Regulation | 21 CFR 878.3300 |
| Device Class | Class 2 |
| Attributes | Therapeutic |
Indications for Use
PSDV-SG is intended for use as a prosthesis for the surgical repair of soft tissue deficiencies using surgical staplers when staple line reinforcement is needed. PSDV-SG can be used for reinforcement of staple lines during bariatric, gastric, small bowel, colon and colorectal procedures.
Device Story
PSDV-SG is an implantable biologic mesh consisting of dehydrated bovine pericardium (Veritas Collagen Matrix) used as a staple line buttress. It features a pre-applied acrylic adhesive strip with a removable liner for secure attachment to surgical stapler cartridges and anvils. Used in bariatric, gastric, small bowel, colon, and colorectal procedures, the device is applied by surgeons to reinforce staple lines. The collagen matrix facilitates neo-collagen formation, neo-vascularization, and eventual remodeling by host tissue. The device is provided sterile for single use. It replaces the hydrogel attachment mechanism of previous versions with a pre-applied adhesive, simplifying preparation for the surgeon. The device is intended for permanent implantation.
Clinical Evidence
Bench testing only. Assessments included visual inspection, thickness, functional testing, manipulation, chemical residuals, heavy metals, endotoxin, bioburden, sterilant residuals, packaging seal strength, preparation time, and stackability. Biocompatibility confirmed via ISO 10993-5:2009 cytotoxicity testing. Human factors study validated usability and labeling comprehension; surgeon validation study confirmed device functionality.
Technological Characteristics
Implantable biologic mesh; non-cross-linked bovine pericardium (from cattle <30 months old); acrylic adhesive. Dimensions: 60mm. Sterilization: Ethylene oxide per AAMI TIR28:2016. Permanent implant. Standalone device.
Indications for Use
Indicated for surgical repair of soft tissue deficiencies using surgical staplers requiring staple line reinforcement in bariatric, gastric, small bowel, colon, and colorectal procedures.
Regulatory Classification
Identification
Surgical mesh is a metallic or polymeric screen intended to be implanted to reinforce soft tissue or bone where weakness exists. Examples of surgical mesh are metallic and polymeric mesh for hernia repair, and acetabular and cement restrictor mesh used during orthopedic surgery.
Predicate Devices
- PERI-STRIPS Dry with VERITAS Collagen Matrix Staple Line Reinforcement (K041669)
- PERI-STRIPS Dry Circular Staple Line Reinforcement with VERITAS Collagen Matrix (K083039)
Reference Devices
- Veritas Collagen Matrix (K002233)
Submission Summary (Full Text)
{0}------------------------------------------------
Image /page/0/Picture/0 description: The image contains the logo of the U.S. Food and Drug Administration (FDA). On the left is the Department of Health and Human Services logo. To the right of that is the FDA logo, which is a blue square with the letters "FDA" in white. To the right of the FDA logo is the text "U.S. FOOD & DRUG ADMINISTRATION" in blue.
December 17, 2019
Synovis Life Technologies, Inc. (Baxter International Inc.) Megan Sajjad Regulatory Affairs Manager 2575 University Ave. W St. Paul, Minnesota 55114
Re: K192615
Trade/Device Name: Peri-Strips Dry with Veritas Collagen Matrix with Secure Grip Technology (PSDV-SG) Regulation Number: 21 CFR 878.3300 Regulation Name: Surgical Mesh Regulatory Class: Class II Product Code: FTM, OXE Dated: September 20, 2019 Received: September 23, 2019
Dear Ms. Sajjad:
We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. Although this letter refers to your product as a device, please be aware that some cleared products may instead be combination products. The 510(k) Premarket Notification Database located at https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpmn/pmn.cfm identifies combination product submissions. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading.
If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.
{1}------------------------------------------------
Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting of medical device-related adverse events) (21 CFR 803) for devices or postmarketing safety reporting (21 CFR 4, Subpart B) for combination products (see https://www.fda.gov/combination-products/guidance-regulatory-information/postmarketing-safety-reportingcombination-products); good manufacturing practice requirements as set forth in the quality systems (OS) regulation (21 CFR Part 820) for devices or current good manufacturing practices (21 CFR 4, Subpart A) for combination products; and, if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.
Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to https://www.fda.gov/medical-device-safety/medical-device-reportingmdr-how-report-medical-device-problems.
For comprehensive regulatory information about medical devices and radiation-emitting products, including information about labeling regulations, please see Device Advice (https://www.fda.gov/medicaldevices/device-advice-comprehensive-regulatory-assistance) and CDRH Learn (https://www.fda.gov/training-and-continuing-education/cdrh-learn). Additionally, you may contact the Division of Industry and Consumer Education (DICE) to ask a question about a specific regulatory topic. See the DICE website (https://www.fda.gov/medical-device-advice-comprehensive-regulatoryassistance/contact-us-division-industry-and-consumer-education-dice) for more information or contact DICE by email (DICE@fda.hhs.gov) or phone (1-800-638-2041 or 301-796-7100).
Sincerely.
Cindy Chowdhury, Ph.D., M.B.A. Acting Assistant Director DHT4B: Division of Infection Control and Plastic Surgery Devices OHT4: Office of Surgical and Infection Control Devices Office of Product Evaluation and Quality Center for Devices and Radiological Health
Enclosure
{2}------------------------------------------------
# Indications for Use
510(k) Number (if known) K192615
Device Name
PERI-STRIPS Dry Staple Line Reinforcement with VERITAS Collagen Matrix with SECURE GRIP Technology
Indications for Use (Describe)
PERI-STRIPS Dry Staple Line Reinforcement with VERITAS Collagen Matrix with SECURE GRIP Technology (PSDV-SG) is intended for use as a prosthesis for the surgical repair of soft tissue deficiencies using surgical staplers when staple line reinforcement is needed.
PSDV-SG can be used for reinforcement of staple lines during bariatric, gastric, small bowel, colon and colorectal procedures.
Type of Use (Select one or both, as applicable)
| <span style="text-decoration: underline;">☑</span> Prescription Use (Part 21 CFR 801 Subpart D) |
|-------------------------------------------------------------------------------------------------|
| <span style="text-decoration: underline;">☐</span> Over-The-Counter Use (21 CFR 801 Subpart C) |
#### CONTINUE ON A SEPARATE PAGE IF NEEDED.
This section applies only to requirements of the Paperwork Reduction Act of 1995.
#### *DO NOT SEND YOUR COMPLETED FORM TO THE PRA STAFF EMAIL ADDRESS BELOW.*
The burden time for this collection of information is estimated to average 79 hours per response, including the time to review instructions, search existing data sources, gather and maintain the data needed and complete and review the collection of information. Send comments regarding this burden estimate or any other aspect of this information collection, including suggestions for reducing this burden, to:
> Department of Health and Human Services Food and Drug Administration Office of Chief Information Officer Paperwork Reduction Act (PRA) Staff PRAStaff@fda.hhs.gov
"An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB number."
{3}------------------------------------------------
#### 510(K) SUMMARY: PERI-STRIPS Dry Staple Line Reinforcement with 5.0 VERITAS Collagen Matrix with SECURE GRIP Technology
#### I. SUBMITTER
Synovis Life Technologies, Inc. (Synovis) (A subsidiary of Baxter International Inc.) 2575 University Avenue West St. Paul, MN 55114-1024
Contact Person: Megan Sajjad, Manager, Regulatory Affairs Tel: 651-796-7410
Date Prepared: September 20, 2019
## II. DEVICE
Device Trade Name: PERI-STRIPS Dry with VERITAS Collagen Matrix with SECURE GRIP Technology
Common Name: Staple Line Reinforcement
Classification Name: MESH, SURGICAL; MESH, SURGICAL, COLLAGEN, STAPLE LINE REINFORCEMENT (21 CFR 878.3300)
Product Code: FTM, OXE
## III. PREDICATE DEVICES
#### Primary Predicate:
PERI-STRIPS Dry with VERITAS Collagen Matrix Staple Line Reinforcement, K041669
## Additional Predicate:
PERI-STRIPS Dry Circular Staple Line Reinforcement with VERITAS Collagen Matrix, K083039
## IV. DEVICE DESCRIPTION
PERI-STRIPS DRY Staple Line Reinforcement with VERITAS Collagen Matrix with SECURE GRIP Technology (PSDV-SG) is prepared from dehydrated bovine pericardium procured from cattle under 30 months of age in the United States.
The product consists of a loading unit which includes two (2) buttresses, one for the anvil (ANV) and one for the cartridge (CART) side of the stapler. Each
{4}------------------------------------------------
## PERI-STRIPS Dry Staple Line Reinforcement with VERITAS Collagen Matrix with SECURE GRIP Technology TRADITIONAL 510K
buttress has acrylic adhesive on one side for attachment to the stapler surfaces. Each PSDV-SG loading unit is packaged sterile in a separate pouch.
PSDV-SG utilizes animal tissue; patient must be informed prior to any procedure.
See Table 1 for product models and configurations.
| Table 1. PSDV-SG Model Numbers and Sizes | | | |
|------------------------------------------|-----------|---------------------------|---------------------------------------------------------------------------------|
| Model Number | Size (mm) | Thickness (mm) per Firing | Stapler Compatibility |
| PSDA60ECH | 60 | 0.45 - 1.26 | Ethicon Echelon 60 ENDOPATH Stapler<br>Ethicon Echelon FLEX 60 ENDOPATH Stapler |
| PSDA60ECHTHN | 60 | 0.45 - 0.86 | Ethicon Echelon 60 ENDOPATH Stapler<br>Ethicon Echelon FLEX 60 ENDOPATH Stapler |
PSDV-SG is provided sterile and intended for single use. Sterilization occurs via ethylene oxide. The bovine pericardium buttress and acrylic adhesive are intended for permanent implant.
# V. INTENDED USE/INDICATIONS FOR USE
## Statement of Intended Use:
PSDV-SG is intended to be used as a staple line buttress.
## Indications for Use
PSDV-SG is intended for use as a prosthesis for the surgical repair of soft tissue deficiencies using surgical staplers when staple line reinforcement is needed.
PSDV-SG can be used for reinforcement of staple lines during bariatric, gastric, small bowel, colon and colorectal procedures.
The Indications for Use for the PSDV-SG product are not identical to the predicate devices, however, the differences do not alter the intended therapeutic use of the device nor do they affect the safety and effectiveness of the device relative to the predicates. Both the subject and predicate devices have the same intended use for staple line buttressing.
#### VI. COMPARISON OF TECHNOLOGICAL CHARACTERISTICS WITH THE PREDICATE DEVICES
The Peri-Strips Dry with Veritas (PSDV) product family are implantable biologic meshes comprised of non-cross-linked bovine pericardium. PSDV is the Veritas® Collagen Matrix (K002233) tissue that has been dried and cut to specification for use with staplers to provide buttress reinforcement at the staple line. PSDV
{5}------------------------------------------------
## PERI-STRIPS Dry Staple Line Reinforcement with VERITAS Collagen Matrix with SECURE GRIP Technology TRADITIONAL 510K
allows for neo-collagen formation and neo-vascularization of the implanted device and permits replacement of the device with host tissue, or remodeling.
PSDV-SG is substantially equivalent to the predicates PERI-STRIPS Dry with VERITAS Collagen Matrix Staple Line Reinforcement (PSDV-L) (K041669) and PERI-STRIPS Dry Circular Staple Line Reinforcement with VERITAS Collagen Matrix (PSDV-C) (K083039) based on having the same fundamental technology and intended use. The PSDV-SG product modifies the current PSDV-L product by replacing the hydrogel accessory component, used for the securement of the PSDV-L tissue buttress to a surgical stapler, with a pre-applied adhesive strip. The pre-applied adhesive strip is protected by a removable liner with pull tab until time of use. The adhesive strip being added is the same material that is used in the current PSDV-C product.
The subject and predicate devices are identical in the following respects:
- Same Intended Use (PSDV-L and PSDV-C) ●
- Same buttress material (PSDV-L and PSDV-C) ●
- Same adhesive material (PSDV-C)
- Same tissue dimensions, loading unit and stapler compatibility (PSDV-L ● 60 ECH configuration)
- Same packaging materials (PSDV-L) ●
- Same method of sterilization (PSDV-L and PSDV-C)
The following technological differences exist between the subject and predicate devices:
- o Different mechanism of attachment of the tissue buttress to stapler compared to PSDV-L
- Different adhesive coat weight and dimensions compared to PSDV-C ●
- Narrowed indications for use compared to the cleared indications for . PSDV-L and PSDV-C
#### VII. PERFORMANCE DATA
The following performance data were provided in support of the substantial equivalence determination:
Pre-Clinical Bench Studies
Design verification of the PSDV-SG device consisted of the following assessments:
- Visual Inspection
- Thickness ●
- Functional Testing ●
- Manipulation Testing ●
- Chemical residuals ●
- Drape
{6}------------------------------------------------
## PERI-STRIPS Dry Staple Line Reinforcement with VERITAS Collagen Matrix with SECURE GRIP Technology TRADITIONAL 510K
- Heavy Metals ●
- Endotoxin
- Bioburden ●
- Sterilant residuals
- Seal strength of packaging seals ●
- Preparation time
- Stackability ●
The results of new bench testing, along with applicable historical testing utilizing PSDV-L or PSDV-C, demonstrate the performance of the PSDV-SG device is substantially equivalent to the predicate devices.
#### Biocompatibility
All patient contacting materials found in the PSDV-SG device have been previously cleared under Synovis premarket notifications K041669 and K083039. In order to confirm that modifications in the manufacturing process of PSDV-SG have no impact on the biocompatibility of the device, confirmatory cytotoxicity testing was conducted according to ISO 10993-5:2009 L929 elution method. Testing passed the acceptance criteria.
#### Shelf Life
Synovis has performed aging testing to support a 6 month shelf life claim. Testing at additional timepoints is ongoing and the product shelf life will be extended as stability data justifies.
#### Sterilization
PSDV-SG will be adopted into the existing sterilization cycle for PSDV-L and PSDV-C per AAMI TIR28:2016 Product adoption and process equivalence for ethylene oxide sterilization.
## Validation Studies
A human factors study was successfully completed demonstrating the usability of the product and user comprehension of the labeling. A surgeon validation was additionally completed and supports customer satisfaction of the PSDV-SG functionality.
## VIII. CONCLUSION
PSDV-SG shares the same intended use and technological characteristics as the predicate devices. The physical, functional and performance specifications for the device are substantially equivalent. There are no different questions of safety and effectiveness of PSDV-SG as compared to the predicate devices. Testing supports that PSDV-SG is as safe and effective as the predicate PSDV-L and PSDV-C devices when used according to its labeling.
